Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04169009 · ClinicalTrials.gov registry record · Phase 4
Persistence of Protection by Shingrix
A Phase 4 study of Herpes Zoster, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- Phase 4
- Development phase
- 105
- Enrollment target
- 1
- Study location
NCT04169009 is a Phase 4 study of Herpes Zoster that has completed, run by University of Colorado, Denver. The registered enrollment target is 105 participants, below the 2,167-participant average among 16 other Herpes Zoster trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04169009, a Phase 4 study of Herpes Zoster, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 105 participants
- Enrollment target
- 1
- Study location
Study Summary
The study plans to learn more about how the shingles vaccine, Shingrix (SRX), successfully prevents shingles in older people. Two vaccines are currently approved by the Food and Drug Administration (FDA) to prevent shingles. Zostavax is a live virus vaccine which has been available since 2006 and prevents shingles about 50% of the time, though it is less effective the older a person is when they receive it. Shingrix, which was approved by the FDA in 2017, is not a live virus, but has an additive in the vaccine to boost immune response. It is about 97% effective at preventing shingles regardless of a person's age and so far has been effective for at least 4 years after vaccination. Because Zostavax has live virus in it, giving a "challenge" dose of Zostavax - vOka varicella zoster virus - to people who have received both vaccines (Zostavax or Shingrix) in the past, will allow researchers to learn more about how the body works to prevent shingles and how any shingles vaccination helps protect against shingles.
Conditions Studied
Interventions
- BIOLOGICAL Shingrix
- BIOLOGICAL Zostavax
Study Locations (1)
Colorado
- Clinical Trials Center at University of Colorado Anschutz Medical Center - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2020-07-28 |
| Est. Completion | 2024-06-13 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04169009
The ClinicalTrials.gov registry entry for NCT04169009 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 105 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,167-participant average among 16 other Herpes Zoster trials with a reported enrollment target (95% lower). The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Herpes Zoster appearing as the primary indexed condition, and to 2 interventions - of which Shingrix is the first listed.
NCT04169009 reports 1 study location spanning 1 distinct geographic area - top geographies include Colorado.
Frequently Asked Questions
What is clinical trial NCT04169009 about?
NCT04169009 is a clinical study titled "Persistence of Protection by Shingrix". The study plans to learn more about how the shingles vaccine, Shingrix (SRX), successfully prevents shingles in older people. Two vaccines are currently approved by the Food and Drug Administration (FDA) to prevent shingles. Zostavax is a live virus vaccine which has been available since 2006 and pr...
What is the current status of trial NCT04169009?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 105 participants. The study started on 2020-07-28. Estimated completion is 2024-06-13.
What conditions does trial NCT04169009 study?
This clinical trial studies the following conditions: Herpes Zoster.
What interventions are being tested in trial NCT04169009?
The interventions under investigation include: Shingrix (BIOLOGICAL), Zostavax (BIOLOGICAL).
Who is sponsoring clinical trial NCT04169009?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04169009 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Herpes Zoster
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control Population
RECRUITING · Phase 1
-
Safety of Herpes Zoster Subunit (HZ/su) Vaccine During Pregnancy in Adult Women With Immunocompromised Conditions
ACTIVE NOT RECRUITING
-
Safety and Immunogenicity of CRV-101 Vaccine for the Prevention of Herpes Zoster in Adults Aged 50 Years and Older
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants
ACTIVE NOT RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ≥50 Years of Age
ACTIVE NOT RECRUITING · Phase 1
-
A Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older Adults
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.